Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

NCT05646303 is registered in ClinicalTrials.gov with Clairvoyant Therapeutics as lead sponsor.

NCT NCT05646303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05646303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)
Lead sponsor
Clairvoyant Therapeutics
Phase
Phase 2
Overall status
Unknown status
Start date
May 2, 2022
Completion date
December 31, 2024
Enrollment
128 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder